Connect your AI

Lexicon Pharmaceuticals LXRX Price / book

Price / book at other companies

Eli LillyLLY

26.3×-20.7×

PfizerPFE

1.8×+0.2×

Merck & Co.MRK

6.5×+1.8×

Vertex PharmaceuticalsVRTX

5.9×-1.7×

CytokineticsCYTK

58.5×—

Zevra Therapeutics, Inc.ZVRA

2.7×-7.2×

Other financials

Income statement

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Balance sheet

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Cash flow

Operating cash flow-$14.7M+66.4%

CapEx--100%

Free cash flow-$17.2M+21.5%

Valuation

Market cap$986.12M+262%

Enterprise value$976.73M+209%

P/S14.2×+5.4×

Profitability

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

FCF margin-578.5%-283pp

Returns & leverage

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Where this comes from

Calculated from Lexicon Pharmaceuticals’s reported figures.

market cap/total stockholders equity=3.3×

Based on the most recent quarter.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Lexicon Pharmaceuticals's price / book?: Lexicon Pharmaceuticals (LXRX) reported price / book of 3.3× in Q1 2026.
How has Lexicon Pharmaceuticals's price / book changed year-over-year?: Lexicon Pharmaceuticals's price / book increased by 140.7% year-over-year, from 1.4× to 3.3×.
What is the long-term trend for Lexicon Pharmaceuticals's price / book?: Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's price / book has grown at a 3.6% compound annual growth rate (CAGR), from 3.3× to 3.9×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.